 TheStreet downgraded shares of PDL BioPharma NASDAQ:PDLI from a c- rating to a d rating in a research note issued to investors on Thursday morning, TheStreetRatingsTable reports. Several other equities research analysts have also issued reports on the stock. Cowen restated a hold rating and issued a 3.00 target price on shares of PDL BioPharma ... 